Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30531642 | 1.00 | USP2 (0.30) | USP2LMNACYP3A4MAPTRECQL | |
| SCHEMBL22492465 | 0.80 | KDM4E (0.30) | — | |
| SCHEMBL22492496 | 0.78 | ALDH1A1 (0.35) | USP2LMNACYP3A4MAPTRECQL | |
| SCHEMBL22492376 | 0.77 | NOS3 (0.31) | LMNA | |
| Methane SCHEMBL22492568 | 0.73 | USP2 (0.32) | USP2LMNACYP3A4MAPTRECQL | |
| SCHEMBL22492425 | 0.72 | — | — | |
| SCHEMBL4586536 | 0.71 | CA1 (0.37) | — | |
| SCHEMBL22492567 | 0.70 | USP2 (0.32) | USP2LMNACYP3A4MAPTRECQL | |
| SCHEMBL22492548 | 0.70 | USP2 (0.32) | USP2LMNACYP3A4MAPTRECQL | |
| SCHEMBL22492561 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2024-03-21 | — | — | US | disclosed |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2022-07-21 | — | — | US | disclosed |
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | ULTRAGENYX PHARMACEUTICAL INC. (US) | 2022-05-17 | — | — | US | disclosed |
| US-20210002211-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | ULTRAGENYX PHARMACEUTICAL INC. | 2021-01-07 | — | — | US | disclosed |
| EP-3717453-A2 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | Ultragenyx Pharmaceutical Inc. (US) | 2020-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11332438-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, PYGM, TKT | USP2 2763/4885LMNA 1837/4885CYP3A4 1146/4885 |
| US-20210002211-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | USP2 2763/4885LMNA 1837/4885CYP3A4 1146/4885 |
| US-20240092731-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | USP2 2763/4885LMNA 1837/4885CYP3A4 1146/4885 |
| US-11753369-B2 | Creatine prodrugs, compositions and methods of use thereof | CKMT1A; CKMT1B, PYGM, TKT | USP2 2763/4885LMNA 1837/4885CYP3A4 1146/4885 |
| US-20220227703-A1 | CREATINE PRODRUGS, COMPOSITIONS AND METHODS OF USE THEREOF | CKMT1A; CKMT1B, PYGM, TKT | USP2 2763/4885LMNA 1837/4885CYP3A4 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.